Patients With Third-Party Insurance was GeneDx Holdings’s largest segment in fiscal 2025, bringing in $1.04B of $1.27B (81%).
| Segment | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Patients With Third-Party Insurance | — | $378.80M | $694.63M | $1.04B | |||
| Institutional Customers | $138.37M | $178.49M | $195.35M | $207.14M | |||
| Diagnostic Test | — | $24.57M | $9.47M | $3.08M | |||
| Diagnostic Test Revenue | $351.25M | — | — | — | |||
| Diagnostic Test Revenue: | — | — | — | — | |||
| Other Revenue | $22.08M | $20.74M | $9.88M | $22.34M | |||
| Other Revenue (Including Related Party Revenue Of $232, $3 & $1,180 For The Years Ended December 31, 2021, 2020, And 2019, Respectively) | — | — | — | — | |||
| Self-Pay Patients | $41.83M | $10.10M | $7.03M | $4.08M | |||
| Total | $553.53M | $612.70M | $916.35M | $1.27B |
GeneDx Holdings brought in $1.27B from its five segments in fiscal 2025, the year ended December 31, 2025. That was up 38.8% from $916.35M in fiscal 2024. Patients With Third-Party Insurance was the largest at $1.04B (81.4%), ahead of Institutional Customers at $207.14M (16.3%) and Other Revenue at $22.34M (1.8%). The other two segments brought in $7.16M combined.
Compared with fiscal 2024, Patients With Third-Party Insurance grew 49.1% to $1.04B and Institutional Customers grew 6.0% to $207.14M.
GeneDx Holdings began breaking out Diagnostic Test in fiscal 2023, when it brought in $24.57M. GeneDx Holdings stopped reporting Diagnostic Test Revenue as a separate segment after fiscal 2022, when it brought in $351.25M.
Genedx was GeneDx Holdings’s largest segment in fiscal 2025, bringing in $1.04B of $1.05B (99%).
| Statement Business Segments | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Genedx | $340.93M | $378.80M | $694.63M | $1.04B |
| Legacy Sema4 | $318.31M | — | — | — |
| Other | — | $24.68M | $9.47M | $13.35M |
| Total | $659.24M | $403.47M | $704.10M | $1.05B |
GeneDx Holdings brought in $1.05B from its two segments in fiscal 2025, the year ended December 31, 2025. That is less than the $1.27B it reports by segment, so these segments do not cover all of its revenue. Genedx was the largest at $1.04B (98.7%), ahead of Other at $13.35M (1.3%).
GeneDx Holdings began breaking out Other in fiscal 2023, when it brought in $24.68M. GeneDx Holdings stopped reporting Legacy Sema4 as a separate segment after fiscal 2022, when it brought in $318.31M.
GeneDx Holdings (WGS) reports its revenue by segment and by statement business segments. In fiscal 2025, Patients With Third-Party Insurance was its largest segment, bringing in $1.04B (81.4% of the total), followed by Institutional Customers at $207.14M (16.3%).
Patients With Third-Party Insurance was GeneDx Holdings' largest segment in fiscal 2025, bringing in $1.04B, or 81.4% of the $1.27B total across its five segments.
Patients With Third-Party Insurance grew faster than Institutional Customers in fiscal 2025, up 49.1% from $694.63M to $1.04B. Institutional Customers grew 6.0% to $207.14M.
Every figure comes from GeneDx Holdings' annual financial filings, as reported. Each line keeps the name GeneDx Holdings gives it, and years follow its fiscal calendar.
GeneDx Holdings' revenue by segment goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.